The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ABBVIE INC | Common | 00287Y109 | 711,478 | 10,917,258 | SH | SOLE | 10,641,358 | 0 | 275,900 | ||
ALKERMES PLC | Common | G01767105 | 437,026 | 7,470,528 | SH | SOLE | 7,202,042 | 0 | 268,486 | ||
BIOGEN INC | Common | 09062X103 | 103,021 | 376,788 | SH | SOLE | 350,330 | 0 | 26,458 | ||
BIOVERATIV INC | Common | 09075E100 | 43,076 | 791,264 | SH | SOLE | 668,914 | 0 | 122,350 | ||
GILEAD SCIENCES INC | Common | 375558103 | 107,864 | 1,588,100 | SH | SOLE | 1,588,100 | 0 | 0 | ||
PROTHENA CORP PLC | Common | G72800108 | 619,282 | 11,106,211 | SH | SOLE | 10,586,790 | 0 | 519,421 | ||
THERAVANCE BIOPHARMA INC | Common | G8807B106 | 393,948 | 10,705,108 | SH | SOLE | 9,952,109 | 0 | 752,999 |